^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HLX43

    i
    Other names: HLX43, HLX 43, HLX-43
    Associations

    News

    Trials
    Company:
    Fosun Pharma
    Drug class:
    Topoisomerase I inhibitor, PD-L1-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    DDX5 (DEAD-Box Helicase 5)
    |
    PD-L1 expression
    |
    HLX43
    1year
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • Metastases
    |
    DDX5 (DEAD-Box Helicase 5)
    |
    PD-L1 expression
    |
    HLX43
    over1year
    Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models (ESMO 2023)
    Conclusions HLX43 showed promising efficacy and tolerability in preclinical assessments. It may offer a novel treatment for PD-1/PD-L1 inhibitor R/R cancers like NSCLC, HNSCC, ESCC, MEL, and OVC.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-L1-L
    |
    HLX43